Total Payments
$250,389
2024 Payments
$11,205
Companies
67
Transactions
520
Medicare Patients
2,651
Medicare Billing
$420,668
Payment Breakdown by Category
Consulting$131,810 (52.6%)
Research$67,950 (27.1%)
Travel$26,668 (10.7%)
Other$12,960 (5.2%)
Food & Beverage$10,417 (4.2%)
Education$584.05 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $131,810 | 40 | 52.6% |
| Unspecified | $67,950 | 26 | 27.1% |
| Travel and Lodging | $26,668 | 37 | 10.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,960 | 15 | 5.2% |
| Food and Beverage | $10,417 | 395 | 4.2% |
| Education | $584.05 | 7 | 0.2% |
Payments by Type
General
$182,439
494 transactions
Research
$67,950
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $41,772 | 6 | $0 (2020) |
| Innate Pharma, Inc | $38,453 | 6 | $0 (2021) |
| PFIZER INC. | $38,049 | 71 | $0 (2024) |
| ABBVIE INC. | $25,170 | 41 | $0 (2024) |
| F. Hoffmann-La Roche AG | $17,216 | 4 | $0 (2022) |
| Janssen Research & Development, LLC | $10,328 | 7 | $0 (2017) |
| Theratechnologies Inc. | $9,192 | 7 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $8,812 | 14 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $8,563 | 29 | $0 (2024) |
| Genentech USA, Inc. | $8,059 | 11 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,205 | 67 | Theratechnologies Inc. ($2,926) |
| 2023 | $21,501 | 56 | PFIZER INC. ($7,627) |
| 2022 | $24,508 | 54 | F. Hoffmann-La Roche AG ($17,216) |
| 2021 | $47,698 | 48 | Innate Pharma, Inc ($38,453) |
| 2020 | $12,016 | 15 | PFIZER INC. ($4,200) |
| 2019 | $19,597 | 46 | PFIZER INC. ($12,160) |
| 2018 | $73,454 | 163 | EMD Serono, Inc. ($38,022) |
| 2017 | $40,411 | 71 | Janssen Research & Development, LLC ($10,328) |
All Payment Transactions
520 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $21.59 | General |
| Category: DESMOID TUMORS | ||||||
| 12/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.76 | General |
| 12/17/2024 | Fresenius Kabi USA, LLC | Stimufend (Biological) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: Biosimilars | ||||||
| 12/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $9.68 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $34.07 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: Oncology | ||||||
| 12/03/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $11.34 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.71 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $23.56 | General |
| 11/04/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $24.92 | General |
| 10/01/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: Oncology | ||||||
| 09/24/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $18.62 | General |
| Category: Oncology | ||||||
| 09/19/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: Oncology | ||||||
| 09/13/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $26.09 | General |
| Category: HORMONE THERAPY | ||||||
| 09/05/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $89.95 | General |
| 09/03/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 09/03/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $8.58 | General |
| Category: HEMATOLOGY | ||||||
| 09/01/2024 | Theratechnologies Inc. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 08/28/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $15.47 | General |
| Category: Oncology / Rare Diseases | ||||||
| 08/14/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $16.10 | General |
| 08/11/2024 | Amneal Pharmaceuticals LLC | AVASTIN (Drug), NEULASTA, NEUPOGEN | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: ONCOLOGY | ||||||
| 08/07/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $29.75 | General |
| Category: Oncology | ||||||
| 08/05/2024 | Myocardial Solutions, Inc. | — | Food and Beverage | In-kind items and services | $44.61 | General |
| 07/30/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A phase-I study of the anti-C5aR, IPH5401, in combination with the anti-PDL-1, durvalumab, in patients with selected advanced solid tumors | Innate Pharma, Inc | $38,453 | 6 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $8,178 | 2 |
| GEDATOLISIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
| AMG 820 FIH | Amgen Inc. | $4,136 | 1 |
| COFETUZUMAB PELIDOTIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A Phase 2 Open-label Extension Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 | Astellas Pharma Global Development | $2,289 | 1 |
| GEDATOLISIB PF06840003 PF04691502 PF06939999 PF06650808 ELRANATAMAB PF06952229 PF06821497 PF07265807 PF06804103 TRASTUZUMAB PFIZER PF06664178 PF06940434 NIROGACESTAT PF06671008 TINLORAFENIB PF06753512 MAVELERTI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,400 | 1 |
| A PHASE 2 OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY OF CONTINUED ADMINISTRATION OF MDV3100 IN SUBJECTS WITH PROSTATE CANCER WHO SHOWED BENEFIT FROM PRIOR EXPOSURE TO MDV3100 | Astellas Pharma Global Development | $770.00 | 2 |
| NIROGACESTAT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors | ABBVIE INC. | $129.33 | 2 |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | AbbVie Inc. | $84.83 | 2 |
| A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors | ABBVIE INC. | $40.10 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 328 | 5,672 | $565,147 | $136,542 |
| 2022 | 14 | 371 | 1,811 | $365,845 | $60,256 |
| 2021 | 24 | 658 | 2,731 | $461,476 | $83,000 |
| 2020 | 46 | 1,294 | 7,074 | $835,994 | $140,870 |
Total Patients
2,651
Total Services
17,288
Medicare Billing
$420,668
Procedure Codes
96
All Medicare Procedures & Services
96 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 4,800 | $318,480 | $89,298 | 28.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 100 | 381 | $95,250 | $24,884 | 26.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 37 | 104 | $73,528 | $9,757 | 13.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 49 | 68 | $25,024 | $5,725 | 22.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 14 | 49 | $15,337 | $2,266 | 14.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $7,345 | $1,415 | 19.3% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 17 | 31 | $7,936 | $715.14 | 9.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 21 | 67 | $6,432 | $704.34 | 11.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 18 | 54 | $5,832 | $631.23 | 10.8% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 15 | 23 | $5,681 | $627.07 | 11.0% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 17 | 49 | $3,675 | $454.02 | 12.4% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 15 | 33 | $627.00 | $64.84 | 10.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 93 | 439 | $109,750 | $28,627 | 26.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 42 | 161 | $113,827 | $16,233 | 14.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 51 | 78 | $28,704 | $7,446 | 25.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 23 | 60 | $18,780 | $2,902 | 15.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 24 | 100 | $10,800 | $1,160 | 10.7% |
| 96374 | Injection of drug or substance into vein | Office | 2022 | 21 | 30 | $7,410 | $878.40 | 11.9% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2022 | 15 | 29 | $7,424 | $735.92 | 9.9% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2022 | 22 | 72 | $5,400 | $693.69 | 12.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 13 | 27 | $4,239 | $630.23 | 14.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 13 | 48 | $4,608 | $476.08 | 10.3% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2022 | 13 | 470 | $53,580 | $350.49 | 0.7% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2022 | 18 | 38 | $722.00 | $80.78 | 11.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 11 | 240 | $240.00 | $22.94 | 9.6% |
About Anthony Tolcher
Anthony Tolcher is a Medical Oncology healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1184627663.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Anthony Tolcher has received a total of $250,389 in payments from pharmaceutical and medical device companies, with $11,205 received in 2024. These payments were reported across 520 transactions from 67 companies. The most common payment nature is "Consulting Fee" ($131,810).
As a Medicare-enrolled provider, Tolcher has provided services to 2,651 Medicare beneficiaries, totaling 17,288 services with total Medicare billing of $420,668. Data is available for 4 years (2020–2023), covering 96 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location San Antonio, TX
- Active Since 05/27/2005
- Last Updated 03/12/2021
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1184627663
Products in Payments
- Lumoxiti (Drug) $38,453
- Non-Covered Product (Drug) $7,875
- XCOPRI (Drug) $3,750
- Enzalutamide (Drug) $2,289
- ENHERTU (Biological) $2,188
- Leukine (Drug) $2,000
- ELREXFIO (Drug) $1,400
- ASB183X (Drug) $992.11
- ENZALUTAMIDE (Drug) $770.00
- MK-8353 (Drug) $763.26
- ERLEADA (Drug) $426.52
- KEYTRUDA (Biological) $251.25
- Stivarga (Drug) $241.96
- LYNPARZA (Drug) $210.84
- LUMAKRAS (Drug) $188.90
- Enhertu (Drug) $176.39
- Cabometyx (Drug) $156.62
- PRECISETUMOR (Device) $154.55
- Onivyde (Drug) $153.01
- OPDIVO (Biological) $152.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in San Antonio
Dr. Vijay Gunuganti, M.d, M.D
Medical Oncology — Payments: $1.8M
Medical Oncology $1.8M
Virginia Kaklamani, Md, MD
Medical Oncology — Payments: $905,581
Medical Oncology $905,581
Dr. John Sarantopoulos, M.d, M.D
Medical Oncology — Payments: $745,925
Medical Oncology $745,925
Dr. Amita Patnaik, M.d, M.D
Medical Oncology — Payments: $150,997
Medical Oncology $150,997
Muralidhar Beeram, M.d, M.D
Medical Oncology — Payments: $119,186
Medical Oncology $119,186
Mrs. Nosha Farhadfar, M.d, M.D
Medical Oncology — Payments: $53,045
Medical Oncology $53,045